Land: Storbritannia
Språk: engelsk
Kilde: VMD (Veterinary Medicines Directorate)
Thiamazole
Dechra Limited
QH03BB02
Thiamazole
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Cats
Anti Hormone Agent
Authorized
2002-01-22
Revised: November 2021 AN: 00279/2021 & 00281/2021 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Felimazole 5 mg Coated Tablets for Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Thiamazole 5mg EXCIPIENTS: Titanium Dioxide (E171) 0.495mg Beta Carotene (E160a) 0.16 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Coated tablet. Orange sugar-coated biconvex tablets 5.5 mm diameter. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long-term treatment of feline hyperthyroidism. 4.3 CONTRAINDICATIONS Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in cats with hypersensitivity to thiamazole or the excipient, polyethylene glycol. Do not use in pregnant or lactating females. Please refer to section 4.7. Revised: November 2021 AN: 00279/2021 & 00281/2021 Page 2 of 6 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES As thiamazole can cause haemoconcentration, cats should always have access to drinking water. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS If more than 10 mg per day is required animals should be monitored particularly carefully. Use of the product in cats with renal dysfunction should be subject to careful risk : benefit assessment by the clinician. Due to the effect thiamazole can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur. Haematology must be monitored due to risk of leucopenia or haemolytic anaemia Les hele dokumentet